Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics

BACKGROUND: A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an oral prodrug of 5‐fluorouracil (5‐FU). Capecitabine and its metabolites are highly water‐soluble and, therefore, more likely to distribute to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Molenaar‐Kuijsten, Laura, Jacobs, Bart Albertus Wilhelmus, Kurk, Sophie Alberdine, May, Anne Maria, Dorlo, Thomas Petrus Catharina, Beijnen, Jacob Hendrik, Steeghs, Neeltje, Huitema, Alwin Dagmar Redmar
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290233/
https://ncbi.nlm.nih.gov/pubmed/34121365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.4038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados